Futura has developed a highly efficient and proprietary delivery technology DermaSys® for the absorption of active molecules through the skin. The DermaSys® technology was originally developed by Futura for use in our topical treatment for erectile dysfunction, MED2002. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
We are in non-exclusive discussions for the distribution rights to our product for topical pain relief TPR100, which utilises DermaSys®.
To further maximise the value of this asset, Futura has been evaluating its use with a range of compounds and in a range of indications.
In the process of developing PET500 and RAD100, Futura also expanded its DermaSys® delivery technology platform and produced a new and unique delivery system which does not contain any water, DermaSys® AquaFree.